drugset / Trial / NCT00827840
Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia
Phase 4
Completed
58 enrolled
Chonnam National University Hospital
Janssen Korea, Ltd., Korea · collabMinistry of Health, Republic of Korea · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary objective: To examine whether the switch to paliperidone ER from risperidone improves cognitive function in stabilized patients with schizophrenia. Secondary objectives: To compare the general clinical outcomes (efficacy and safety) after switching to paliperidone ER from risperidone
Timeline
- Start
- 2008-11
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paliperidone | Unknown | 3 mg | — |
| Subject | Paliperidone | Unknown | 12 mg | — |
| Comparator | Risperidone | Other / unclassified | 1 mg | — |
| Comparator | Risperidone | Other / unclassified | 6 mg | — |